Alyeska Investment Group
GNCA

Alyeska Investment Group’s Genocea Biosciences, Inc. GNCA Stock Holding History

Alyeska Investment Group’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-128,203
Closed -$347K – 1043
2021
Q1 		$347K Hold
128,203
– – ﹤0.01% 689
2020
Q4 		$310K Sell
128,203
-1,026
-0.8% -$2.34K ﹤0.01% 470
2020
Q3 		$296K Sell
129,229
-13,292
-9% -$34.9K ﹤0.01% 436
2020
Q2 		$328K Sell
142,521
-108,316
-43% -$249K 0.01% 450
2020
Q1 		$431K Sell
250,837
-40,166
-14% -$81.2K 0.01% 334
2019
Q4 		$602K Buy
291,003
+1,104
+0.4% +$2.62K 0.01% 348
2019
Q3 		$841K Sell
289,899
-6,163
-2% -$21K 0.01% 333
2019
Q2 		$1.16M Buy
+296,062
New +$1.54M 0.02% 360
2018
Q3 		– Sell
-200,386
Closed -$1.06M – 570
2018
Q2 		$1.37M Sell
200,386
-28,965
-13% -$217K 0.01% 377
2018
Q1 		$1.93M Buy
+229,351
New +$1.9M 0.02% 348
2017
Q2 		– Sell
-27,868
Closed -$1.36M – 594
2017
Q1 		$1.36M Sell
27,868
-328
-1% -$12.8K 0.01% 419
2016
Q4 		$929K Buy
28,196
+225
+0.8% +$7.41K 0.01% 427
2016
Q3 		$1.15M Buy
27,971
+1,113
+4% +$43.7K 0.01% 411
2016
Q2 		$881K Buy
26,858
+545
+2% +$20K 0.01% 392
2016
Q1 		$1.63M Buy
26,313
+5,831
+28% +$185K 0.02% 344
2015
Q4 		$864K Sell
20,482
-2,289
-10% -$109K 0.01% 346
2015
Q3 		$1.25M Buy
22,771
+19,971
+713% +$1.98M 0.01% 370
2015
Q2 		$308K Sell
2,800
-9,828
-78% -$912K ﹤0.01% 470
2015
Q1 		$1.2M Buy
12,628
+9,614
+319% +$678K 0.02% 422
2014
Q4 		$169K Sell
3,014
-111
-4% -$7.58K ﹤0.01% 470
2014
Q3 		$226K Buy
+3,125
New +$342K ﹤0.01% 368

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Alyeska Investment Group's GNCA Position: Q2 2021 in Review

Alyeska Investment Group sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2021, closing a stake of 128,203 shares — an estimated $347K sold.

Alyeska Investment Group first reported a position in GNCA in Q3 2014 and held it in 21 quarters. The position peaked at $1.93M in Q1 2018. 46 funds tracked by Wall St. Rank hold GNCA as of Q2 2021.

  • Alyeska Investment Group reported no remaining Genocea Biosciences, Inc. position as of Q2 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 128,203 Genocea Biosciences, Inc. shares in Q2 2021, an estimated $347K.
  • Alyeska Investment Group first reported a position in Genocea Biosciences, Inc. in Q3 2014 and held it in 21 quarters.
  • Alyeska Investment Group's Genocea Biosciences, Inc. position peaked at $1.93M in Q1 2018.
  • 46 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2021.

Based on Alyeska Investment Group's 13F filing for Q2 2021, filed 16 Aug 2021.